Ulcerative colitis, autoimmune hemolytic anemia and primary sclerosing cholangitis in a child

SUSAN MG ILMOUR MD FRCPC, PETER CHAIT MD FRCPC, MJAMES PHILLIPS MD CM FRCPC FRCPath, EVE A ROBERTS MD FRCPC

A utoimmune phenomena may be prominent in inflammatory bowel disease. Ulcerative colitis (UC), in particular, exhibits a high incidence of associated autoimmune diseases including hypothyroidism, primary sclerosing cholangitis (PSC), vitiligo and alopecia areata (1). Autoimmune hemolytic anemia (AIHA) is well described in 0.5% to 1.0% of adult UC patients but has not been reported in children with UC. A 15-month-old female who initially presented with AIHA is described. She developed bloody stools and was diagnosed with ulcerative colitis (UC). Investigations of persistent hepatomegaly revealed primary sclerosing cholangitis (PSC). The association of AIHA, UC and PSC has never been reported. All these conditions entail impaired immunoregulation. Patients with a clustering of autoimmune diseases may help to delineate the pathogenesis of UC. A utoimmune phenomena may be prominent in inflammatory bowel disease. UC, in particular, exhibits a high incidence of associated autoimmune diseases including hypothyroidism, PSC, vitiligo and alopecia areata (1). Autoimmune hemolytic anemia (AIHA) is well described in 0.5% to 1.0% of adult UC patients but has not been reported in children with UC.

Key Words: Autoimmune hemolytic anemia, Autoimmune phenomena, Child, Primary sclerosing cholangitis, Ulcerative colitis

CASE PRESENTATION

A previously well 15-month-old female presented in October 1993 with low grade fever, coryza, lethargy, pallor and jaundice. Her liver was firm and palpable 2 cm below the right costal margin, and her spleen was palpable 2 cm below the left costal margin. Complete blood count revealed: hemoglobin 64 g/L (normal 110 to 140 g/L); total white blood cell count 19.8 x 10^9/L (5 to 12 x 10^9/L); platelets 446 x 10^9/L (150 to 450 x 10^9/L); and reticulocytes 464 x 10^9/L (10 to 100 x 10^9/L). Direct Coombs’ test was positive. Total serum bilirubin was 94 µmol/L (normal less than 17 µmol/L), with a direct component of 23 µmol/L (0 to 7 µmol/L). Further hematological investigation revealed a positive direct antiglobulin test, with specific anti-immunoglobulin (Ig) G and anti-C3d.

The Hospital for Sick Children, University of Toronto, Toronto, Ontario
Correspondence: Dr SM Gilmour, Division of Gastroenterology and Nutrition, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8. Telephone 416-813-6131, fax 416-813-6531
The child was diagnosed with warm-antibody AIHA and started on prednisone 2 mg/kg/day. She responded quickly to therapy; within one week hemoglobin was 91 g/L and reticulocytes 667 x 10^9/L. Physical examination revealed that both liver and spleen were smaller. By December 1993 the patient was well, with a hemoglobin level of 111 g/L. By March 1994 she had been weaned off steroids.

Although the patient was free from hemolysis she continued to have hepatomegaly. Between June and September 1994, her spleen enlarged massively until it was palpable near the left iliac crest. In November 1994, following the first episode of hemolysis since presentation, she was transfused and started on prednisone. At that time liver function tests were aspartate aminotransferase (AST) 302 U/L (normal less than 45 U/L); alanine aminotransferase (ALT) 589 U/L (less than 45 U/L); and alkaline phosphatase 487 U/L (185 to 520 U/L). One month later abdominal sonography showed mild hepatosplenomegaly with mild dilation of intrahepatic bile ducts and a widened common bile duct, but no cholelithiasis or choledocholithiasis.

In February 1995 the patient presented with a 12-day history of bright red blood mixed with stool occurring two to three times/day. There was no night-time stooling, urgency, abdominal pain, fever or vomiting. The patient’s mother indicated that hematochezia had occurred intermittently during the previous 15 months. Stool cultures for bacteria, viruses and parasites were negative, as was a Meckel scan. Hepatosplenomegaly was again noted. Laboratory data revealed AST 291 U/L; ALT 442 U/L; ALP 438 U/L; and γ-glutamyl transpeptidase 505 U/L (normal less than 45 U/L). Total bilirubin was 49 µmol/L and conjugated bilirubin was less than 1 µmol/L. Prothrombin time was normal at 11.2 s. Further investigations revealed mildly elevated IgG (19 g/L; normal 4 to 12 g/L), and normal IgA (1 g/L) and IgM (1.7 g/L). Antinuclear factor was positive at 1/320 with a homogeneous nucleolar pattern. Antismooth muscle antibody was also positive at 1/80. No defects in cellular or humoral immunity were identified.

Further investigations were consistent with UC. Colonoscopy revealed a diffusely friable mucosa up to the ascending colon. Colonic biopsies showed mild to moderate inflammation with inflammatory cells within the lamina propria, and focal areas of pericryptitis. The patient was started on sulphasalazine. Percutaneous liver biopsy revealed chronic hepatitis with marked piecemeal necrosis, extensive ductular proliferation and moderate cholangitis (Figure 1). Percutaneous cholangiogram showed irregular intrahepatic ducts with ‘pruning’ of the ducts, thus confirming the diagnosis of PSC (Figure 2).

**DISCUSSION**

A unique triad of AIHA, UC and PSC is seen in our patient. The association between UC and PSC, and between UC and AIHA is well known. PSC is found in 3% to 7% of adult UC patients (3). Conversely, 70% of adult PSC patients have UC (4). AIHA has been reported in 0.5% to 1.0% of adult UC patients, but there are only two cases in the literature of AIHA and PSC (2,5,6). The constellation of UC, PSC and AIHA has never been reported.

PSC is not uncommon in children and may be associated with colitis (4,7). Children with PSC may be more difficult to identify for several reasons. First, the association between UC and PSC is lower in children; in the largest North American series, only 55% had inflammatory bowel disease and half of these developed it after onset of PSC (4). Second, PSC in children differs from that in adults; PSC in children frequently is limited to intrahepatic bile ducts. Thus, presentation with jaundice and increased ALP is less common than in adults. Finally, PSC in children is diagnosed on the basis of cholangiographic findings: strictures, or dilation or irregu-
larities of the intra- or extrahepatic bile ducts. Elevated serum IgG and positive antismooth muscle and antinuclear antibodies occur commonly in children with PSC, and liver histology often has features suggestive of autoimmune hepatitis (4,8). Whether PSC mimics autoimmune hepatitis or both are manifestations of a single disease process causing autoimmune hepatic disease remains uncertain.

Immunological abnormalities are important in the pathogenesis of PSC and UC. Both conditions have been associated with elevated immunoglobulins, with abnormal autoantibodies against liver cells in PSC and against colonic epithelium in UC (9,10). Immunosuppressive therapy, such as prednisone and cyclosporine, is effective in UC (11). AIHA results from impaired immunoregulation. Recent in vitro work in AIHA indicates that colonic mononuclear cells may be the origin of the red cell antibodies when AIHA is associated with UC (12). Some patients have had resolution of anemia with colectomy, thereby indicating that the colon may be associated with the production of anti-erythrocyte antibodies (13). Because PSC may progress after colectomy, such a similar causal relationship has not been established between colonic disease and PSC.

CONCLUSIONS

We report a child with AIHA, UC and PSC. While there have been only two previous reports of the association of AIHA and PSC, and one report of AIHA, Crohn’s disease and PSC, all three conditions have the features of impaired immunoregulation (5,6,14). Abnormal activation of the humoral immune system is common to all these disorders. Patients who present with unique combinations of these autoimmune conditions, as did our reported child, provide important clues to the pathogenesis of UC.

ACKNOWLEDGEMENTS: This paper was a winning entry in the Inflammatory Bowel Disease Resident Case Study Competition, supported by an educational grant from Astra Pharma Inc. Dr Gilmour is supported by a Duncan Gordan Fellowship of The Hospital for Sick Children Foundation and by a Janssen Pharmaceutica research scholarship.

REFERENCES
